Clinical Study - C3Medline
Eur J Drug Metab Pharmacokinet 1990 Oct-Dec;15(4):333-8
Pharmacokinetic studies on IdB 1016 (Siliphos®), a silybin- phosphatidylcholine complex, in healthy human subjects.
Barzaghi N, Crema F, Gatti G, Pifferi G, Perucca E
Department of Medical Pharmacology, University of Pavia, Italy.
IdB 1016 (Siliphos®) is a complex of silybin (the main active component of silymarin) and phosphatidylcholine, which in animal models shows greater oral bioavailability and therefore greater pharmacological activity compared with pure silybin and silymarin. In order to assess its pharmacokinetic profile in man, plasma silybin levels were determined after administration of single oral doses of IdB 1016 (Siliphos®) and silymarin (equivalent to 360 mg silybin) to 9 healthy volunteers.
Although absorption was rapid with both preparations, the bioavailability of IdB 1016 (Siliphos®) was much greater than that of silymarin, as indicated by higher plasma silybin levels at all sampling times after intake of the complex. Regardless of the preparation used, the terminal half-life was relatively short (generally less than 4 h).
In a subsequent study, 9 healthy volunteers received IdB 1016 (120 mg b.i.d., expressed as silybin equivalents) for 8 consecutive days. The plasma silybin level profiles and kinetic parameters on day 1 were similar to those determined on day 8. Most of the silybin present in the systemic circulation was in conjugated form.
Less than 3% of the administered dose was accounted for by urinary recovery of free plus conjugated silybin, a significant proportion of the dose probably being excreted in the bile.
It is concluded that complexation with phosphatidylcholine in IdB 1016 (Siliphos®) greatly increases the oral bioavailability of silybin, probably by facilitating its passage across the gastrointestinal mucosa.
* Clinical trial
* Randomized controlled trial
PMID: 2088770, UI: 91209372